Pages that link to "Q40506711"
Jump to navigation
Jump to search
The following pages link to Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer (Q40506711):
Displaying 50 items.
- Gene expression analysis for predicting gemcitabine resistance in human cholangiocarcinoma (Q28308112) (← links)
- Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer (Q28396304) (← links)
- DNA methylation-independent reversion of gemcitabine resistance by hydralazine in cervical cancer cells (Q28481440) (← links)
- The relation between deoxycytidine kinase activity and the radiosensitising effect of gemcitabine in eight different human tumour cell lines (Q33245149) (← links)
- Laser microdissection and primary cell cultures improve pharmacogenetic analysis in pancreatic adenocarcinoma. (Q33336057) (← links)
- Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity (Q33575608) (← links)
- Gemcitabine for the treatment of advanced nonsmall cell lung cancer (Q33915997) (← links)
- Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer (Q34254837) (← links)
- PharmGKB summary: gemcitabine pathway (Q34435450) (← links)
- Hippo pathway mediates resistance to cytotoxic drugs (Q34555337) (← links)
- Equilibrative nucleoside transporter 1 genotype, cytidine deaminase activity and age predict gemcitabine plasma clearance in patients with solid tumours (Q34609029) (← links)
- Clinical pharmacology and pharmacogenetics of gemcitabine (Q34985979) (← links)
- The C-terminal region of Bfl-1 sensitizes non-small cell lung cancer to gemcitabine-induced apoptosis by suppressing NF-κB activity and down-regulating Bfl-1 (Q35194201) (← links)
- An increase of cytochrome C oxidase mediated disruption of gemcitabine incorporation into DNA in a resistant KB clone (Q35945507) (← links)
- Personalized therapy for pancreatic cancer: Myth or reality in 2010? (Q36097060) (← links)
- Gemcitabine in metastatic breast cancer (Q36185611) (← links)
- Aptamer-mediated delivery of chemotherapy to pancreatic cancer cells (Q36298003) (← links)
- Enhancing Drug Efficacy and Therapeutic Index through Cheminformatics-Based Selection of Small Molecule Binary Weapons That Improve Transporter-Mediated Targeting: A Cytotoxicity System Based on Gemcitabine (Q36342657) (← links)
- Pyrimidine and purine analogues, effects on cell cycle regulation and the role of cell cycle inhibitors to enhance their cytotoxicity (Q36378036) (← links)
- Role of gemcitabine in cancer therapy (Q36429373) (← links)
- In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients. (Q36612195) (← links)
- Pancreatic cancer: why is it so hard to treat? (Q36886497) (← links)
- Gemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expression (Q36924856) (← links)
- Gemcitabine sensitivity-related mRNA expression in endoscopic ultrasound-guided fine-needle aspiration biopsy of unresectable pancreatic cancer (Q37249378) (← links)
- Pharmacogenetics and pharmacoepigenetics of gemcitabine (Q37630418) (← links)
- ABCB1 and ABCC11 confer resistance to eribulin in breast cancer cell lines (Q37688480) (← links)
- Human nucleoside transporters: biomarkers for response to nucleoside drugs. (Q37698437) (← links)
- Enhanced tumor delivery of gemcitabine via PEG-DSPE/TPGS mixed micelles. (Q37714232) (← links)
- Impact of biomarkers on non-small cell lung cancer treatment (Q37742492) (← links)
- Molecular Predictors of Prognosis in Lung Cancer (Q37913090) (← links)
- Pharmacogenetics of conventional chemotherapy in non-small-cell lung cancer: a changing landscape? (Q38030053) (← links)
- Adjuvant pharmacotherapy in the management of elderly patients with pancreatic cancer (Q38075827) (← links)
- Prognostic and predictive factors in patients treated with chemotherapy for advanced urothelial cancer: where do we stand? (Q38312045) (← links)
- Pharmacogenomics in the treatment of lung cancer: an update (Q38596926) (← links)
- Effect of Hypoxanthine on Functional Activity of Nucleoside Transporters ENT1 and ENT2 in Caco-2 Polar Epithelial Intestinal Cells (Q38817729) (← links)
- Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape (Q38922208) (← links)
- Preclinical rationale for synergistic interaction of pemetrexed and cytotoxic nucleoside analogues (Q39280587) (← links)
- Attenuation of phosphorylation by deoxycytidine kinase is key to acquired gemcitabine resistance in a pancreatic cancer cell line: targeted proteomic and metabolomic analyses in PK9 cells. (Q39379544) (← links)
- Expression of gemcitabine- and cisplatin-related genes in non-small-cell lung cancer. (Q39776948) (← links)
- Novel regulation of equlibrative nucleoside transporter 1 (ENT1) by receptor-stimulated Ca2+-dependent calmodulin binding. (Q39892650) (← links)
- Immunocytochemical detection of hENT1 and hCNT1 in normal tissues, lung cancer cell lines, and NSCLC patient samples (Q39965228) (← links)
- Effect of gemcitabine on the expression of apoptosis-related genes in human pancreatic cancer cells (Q40298723) (← links)
- Variability of gemcitabine accumulation and its relationship to expression of nucleoside transporters in peripheral blood mononuclear cells (Q42717833) (← links)
- Is gemcitabine cost effective in cancer treatment? (Q43042833) (← links)
- Pancreatic Cancer Chemoresistance to Gemcitabine (Q47135556) (← links)
- MiR-608 regulating the expression of ribonucleotide reductase M1 and cytidine deaminase is repressed through induced gemcitabine chemoresistance in pancreatic cancer cells. (Q47830761) (← links)
- Novel Gemcitabine Conjugated Albumin Nanoparticles: a Potential Strategy to Enhance Drug Efficacy in Pancreatic Cancer Treatment. (Q48696930) (← links)
- Cellular localization and functional characterization of the equilibrative nucleoside transporters of antitumor nucleosides (Q50669049) (← links)
- Functional Characterization of the Saccharomyces cerevisiae Equilibrative Nucleoside Transporter 1 (ScENT1). (Q51736626) (← links)
- 5'-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lung cancer. (Q52584335) (← links)